Danaher Corporation $DHR Shares Sold by Generali Asset Management SPA SGR

Generali Asset Management SPA SGR trimmed its holdings in Danaher Corporation (NYSE:DHR) by 5.0% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 59,821 shares of the conglomerate’s stock after selling 3,176 shares during the period. Generali Asset Management SPA SGR’s holdings in Danaher were worth $11,860,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. White Pine Capital LLC increased its stake in shares of Danaher by 1.4% during the 2nd quarter. White Pine Capital LLC now owns 3,494 shares of the conglomerate’s stock worth $690,000 after purchasing an additional 49 shares in the last quarter. Boyd Watterson Asset Management LLC OH grew its holdings in Danaher by 2.1% during the 2nd quarter. Boyd Watterson Asset Management LLC OH now owns 2,524 shares of the conglomerate’s stock valued at $499,000 after buying an additional 51 shares during the last quarter. Worth Financial Advisory Group LLC increased its position in Danaher by 4.6% during the second quarter. Worth Financial Advisory Group LLC now owns 1,195 shares of the conglomerate’s stock worth $236,000 after buying an additional 53 shares in the last quarter. Howard Capital Management Group LLC raised its holdings in shares of Danaher by 4.8% in the third quarter. Howard Capital Management Group LLC now owns 1,159 shares of the conglomerate’s stock worth $230,000 after acquiring an additional 53 shares during the last quarter. Finally, Bruce G. Allen Investments LLC lifted its position in shares of Danaher by 13.1% in the second quarter. Bruce G. Allen Investments LLC now owns 467 shares of the conglomerate’s stock valued at $92,000 after acquiring an additional 54 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Insider Activity

In other news, SVP Brian W. Ellis sold 21,776 shares of the business’s stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $219.23, for a total transaction of $4,773,952.48. Following the completion of the sale, the senior vice president owned 14,553 shares in the company, valued at approximately $3,190,454.19. The trade was a 59.94% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Georgeann Couchara sold 5,174 shares of the stock in a transaction that occurred on Monday, November 10th. The stock was sold at an average price of $210.42, for a total transaction of $1,088,713.08. Following the sale, the senior vice president directly owned 2,625 shares of the company’s stock, valued at approximately $552,352.50. This trade represents a 66.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 30,248 shares of company stock valued at $6,609,663 in the last three months. Corporate insiders own 11.10% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently commented on DHR shares. Bank of America dropped their price objective on Danaher from $230.00 to $220.00 and set a “buy” rating for the company in a research report on Monday, September 22nd. The Goldman Sachs Group assumed coverage on shares of Danaher in a report on Tuesday, December 9th. They set a “buy” rating and a $265.00 price target for the company. Redburn Partners set a $220.00 price objective on shares of Danaher in a research report on Wednesday, October 8th. Morgan Stanley assumed coverage on shares of Danaher in a research report on Monday, December 1st. They set an “overweight” rating and a $270.00 target price on the stock. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Danaher in a report on Monday. Twenty-one investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $248.25.

Danaher Price Performance

Danaher stock opened at $228.99 on Friday. Danaher Corporation has a 1 year low of $171.00 and a 1 year high of $258.23. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.10 and a current ratio of 1.52. The firm has a 50 day moving average price of $223.65 and a 200 day moving average price of $208.90. The company has a market cap of $161.75 billion, a price-to-earnings ratio of 47.21, a PEG ratio of 4.43 and a beta of 0.89.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Monday, October 20th. The conglomerate reported $1.89 earnings per share for the quarter, beating analysts’ consensus estimates of $1.72 by $0.17. The company had revenue of $6.05 billion for the quarter, compared to analyst estimates of $6 billion. Danaher had a net margin of 14.44% and a return on equity of 10.92%. Danaher’s revenue for the quarter was up 4.4% on a year-over-year basis. During the same quarter last year, the business earned $1.71 EPS. Sell-side analysts predict that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 30th. Stockholders of record on Friday, December 26th will be issued a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Friday, December 26th. Danaher’s dividend payout ratio (DPR) is 26.39%.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.